We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

68 hedge funds and large institutions have $158M invested in Eiger BioPharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 24 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 10

140% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 10

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

34% more capital invested

Capital invested by funds: $118M → $158M (+$40.2M)

28% more funds holding

Funds holding: 53 → 68 (+15)

Holders
68
Holders Change
+15
Holders Change %
+28.3%
% of All Funds
1.52%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
25
Increased
24
Reduced
10
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$26M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$11.8M
3
6CM
683 Capital Management
New York
+$10.5M
4
BI
BVF Inc
California
+$7.27M
5
EC
EcoR1 Capital
California
+$5.99M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$15.2M
2
PM
Prosight Management
Texas
-$4.1M
3
IVM
InterWest Venture Management
California
-$3.85M
4
JP Morgan Chase
JP Morgan Chase
New York
-$927K
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$600K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$538K +$456K +1,410 +399%
Acadian Asset Management
27
Acadian Asset Management
Massachusetts
$535K -$374K -1,159 -40%
LCM
28
Laurion Capital Management
New York
$511K +$542K +1,678 New
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$477K +$506K +1,565 New
BFM
30
Boothbay Fund Management
New York
$466K +$494K +1,529 New
CC
31
Caxton Corporation
New Jersey
$444K +$196K +607 +71%
Deutsche Bank
32
Deutsche Bank
Germany
$443K -$117K -362 -20%
Goldman Sachs
33
Goldman Sachs
New York
$443K +$353K +1,094 +304%
Two Sigma Investments
34
Two Sigma Investments
New York
$413K +$169K +524 +63%
Dimensional Fund Advisors
35
Dimensional Fund Advisors
Texas
$373K +$222K +687 +128%
Squarepoint
36
Squarepoint
New York
$372K +$285K +882 +259%
TAM
37
Tocqueville Asset Management
New York
$268K +$102K +315 +56%
EIM
38
Essex Investment Management
Massachusetts
$263K -$278K -859 -50%
Bank of America
39
Bank of America
North Carolina
$263K +$92.4K +286 +50%
Millennium Management
40
Millennium Management
New York
$255K +$270K +836 New
DS
41
DRW Securities
Illinois
$251K +$108K +333 +68%
TI
42
Trexquant Investment
Connecticut
$239K +$254K +785 New
Bank of New York Mellon
43
Bank of New York Mellon
New York
$200K -$2.26K -7 -1%
Wells Fargo
44
Wells Fargo
California
$200K +$174K +539 +445%
PCM
45
Prelude Capital Management
New York
$160K -$142K -439 -45%
BCM
46
BlueCrest Capital Management
Jersey
$160K +$170K +525 New
ECM
47
ExodusPoint Capital Management
New York
$146K +$155K +480 New
PP
48
PDT Partners
New York
$130K +$23.9K +74 +21%
HIM
49
Hillsdale Investment Management
Ontario, Canada
$130K +$138K +427 New
AGM
50
Alpine Global Management
New York
$126K +$133K +413 New
1
2
3 4

EIGR Hedge Fund Activity: Q4 2018 in Review

68 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q4 2018, worth a combined $158M — up 34% from $118M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new EIGR positions and 10 closed out — a net gain of 15 holders — while 24 added to existing stakes and 10 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $26M. The largest seller was Jennison Associates, exiting entirely with an estimated $15.2M sold.

  • 68 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q4 2018, up from 53 in Q3 2018.
  • Funds reported $158M of Eiger BioPharmaceuticals, Inc. stock for Q4 2018, up 34% quarter-over-quarter.
  • 25 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q4 2018 and 10 closed out, a net change of +15 holders.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q4 2018 was RA Capital Management, an estimated $26M added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q4 2018 was Jennison Associates, an estimated $15.2M sold.

Based on aggregated 13F filings for Q4 2018.